These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 25831700)
1. [New oral anticoagulants for thromboprophylaxis under routine use of tranexamic acid after hip joint arthroplasty]. Zhirova TA; Lykov MS; Zyrianov MN; Babushkin VN Anesteziol Reanimatol; 2014; 59(6):34-8. PubMed ID: 25831700 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of tranexamic acid on blood loss after primary cementless total hip replacement with rivaroxaban thromboprophylaxis: A case-control study in 70 patients. Clavé A; Fazilleau F; Dumser D; Lacroix J Orthop Traumatol Surg Res; 2012 Sep; 98(5):484-90. PubMed ID: 22542983 [TBL] [Abstract][Full Text] [Related]
3. Comparison of switch-therapy modalities (enoxaparin to rivaroxaban/dabigatran) and enoxaparin monotherapy after hip and knee replacement. Özler T; Uluçay Ç; Önal A; Altıntaş F Acta Orthop Traumatol Turc; 2015; 49(3):255-9. PubMed ID: 26200403 [TBL] [Abstract][Full Text] [Related]
4. Does tranexamic acid alter the risk of thromboembolism after total hip arthroplasty in the absence of routine chemical thromboprophylaxis? Nishihara S; Hamada M Bone Joint J; 2015 Apr; 97-B(4):458-62. PubMed ID: 25820882 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry. Beyer-Westendorf J; Lützner J; Donath L; Tittl L; Knoth H; Radke OC; Kuhlisch E; Stange T; Hartmann A; Günther KP; Weiss N; Werth S Thromb Haemost; 2013 Jan; 109(1):154-63. PubMed ID: 23197272 [TBL] [Abstract][Full Text] [Related]
6. OBTAIN E: outcome benefits of tranexamic acid in hip arthroplasty with enoxaparin: a randomised double-blinded controlled trial. Fraval A; Duncan S; Murray T; Duggan J; Tirosh O; Tran P Hip Int; 2019 May; 29(3):239-244. PubMed ID: 30039736 [TBL] [Abstract][Full Text] [Related]
7. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Eriksson BI; Dahl OE; Huo MH; Kurth AA; Hantel S; Hermansson K; Schnee JM; Friedman RJ; Thromb Haemost; 2011 Apr; 105(4):721-9. PubMed ID: 21225098 [TBL] [Abstract][Full Text] [Related]
8. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W; N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811 [TBL] [Abstract][Full Text] [Related]
9. Chemical Thromboprophylaxis Is Not Necessary to Reduce Risk of Thromboembolism With Tranexamic Acid After Total Hip Arthroplasty. Kim YH; Park JW; Kim JS J Arthroplasty; 2017 Feb; 32(2):641-644. PubMed ID: 27614816 [TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal. Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028 [TBL] [Abstract][Full Text] [Related]
11. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. Huisman MV; Quinlan DJ; Dahl OE; Schulman S Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996 [TBL] [Abstract][Full Text] [Related]
12. A comparison of complications requiring return to theatre in hip and knee arthroplasty patients taking enoxaparin versus rivaroxaban for thromboprophylaxis. Chahal GS; Saithna A; Brewster M; Gilbody J; Lever S; Khan WS; Foguet P Ortop Traumatol Rehabil; 2013; 15(2):125-9. PubMed ID: 23652532 [TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG; N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812 [TBL] [Abstract][Full Text] [Related]
14. Apixaban and rivaroxaban decrease deep venous thrombosis but not other complications after total hip and total knee arthroplasty. Russell RD; Huo MH J Arthroplasty; 2013 Oct; 28(9):1477-81. PubMed ID: 23540535 [TBL] [Abstract][Full Text] [Related]
15. [Venous thromboembolism prophylaxis after total hip arthroplasty]. Kučera T; Malý R; Urban K; Sponer P Acta Chir Orthop Traumatol Cech; 2011; 78(2):101-5. PubMed ID: 21575551 [TBL] [Abstract][Full Text] [Related]
16. [Dabigatran etexilate use among older adults in a home-care system after hip or knee replacement surgery]. Saimovici JM; La Valle RÁ; Zunino S; Silveira M; Waisman GD Rev Esp Geriatr Gerontol; 2013; 48(3):115-7. PubMed ID: 23473582 [TBL] [Abstract][Full Text] [Related]
17. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery. Colwell C; Mouret P Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914 [TBL] [Abstract][Full Text] [Related]
18. [Tranexamic acid gel in patients treated with oral anticoagulants]. Ripollés-de Ramón J; Muñoz-Corcuera M; Bravo-Llatas C; Bascones-Martínez A Med Clin (Barc); 2014 Dec; 143(11):484-8. PubMed ID: 24268907 [TBL] [Abstract][Full Text] [Related]
19. The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement. Rajesparan K; Biant LC; Ahmad M; Field RE J Bone Joint Surg Br; 2009 Jun; 91(6):776-83. PubMed ID: 19483232 [TBL] [Abstract][Full Text] [Related]
20. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Muehlhofer E; Dierig C; Misselwitz F; Kälebo P; Circulation; 2006 Nov; 114(22):2374-81. PubMed ID: 17116766 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]